Immunotherapy of Urothelial Cancer/Prostate Cancer 10 years experience
|
|
- Gary Freeman
- 5 years ago
- Views:
Transcription
1 Immunotherapy of Urothelial Cancer/Prostate Cancer 10 years experience Prof Winald R. Gerritsen Radboud University Medical Center Department of Medical Oncology Nijmegen, the Netherlands Adjunct Professor Johns Hopkins Sidney Kimmel Cancer Center Baltimore, USA
2 Disclosures last five years Speaker fees Astellas (personal), Bayer (institute), MSD (institute), ESMO (institute) Advisory boards Amgen (personal), Bayer (institute), Bristol-Myers Squibb (institute), Curevac (personal), Dendreon (personal), IMS Health/iQVia (institute), Janssen-Cilag (institute), Merck (MSD) (institute), Morphosys (institute), Sanofi (personal), Research grants Astellas (institute), Bayer (institute), Janssen-Cilag (institute), Sanofi (institute)
3 Sources: 1. J Bellmunt et al EJC suppl 2016: 14(1): BCAN: Bladder cancer Advocacy Network: www. Bcan.org Immunotherapy of urothelial cancers Module 1: Diagnosis and incidence of urothelial cancer In Europe 118,365 diagnosed in K + living with bladder cancer 5th most common cancer 39,522 died in 2012 Statistics are human beings with the tears wiped away. 50% - 80% recurrence rate 4th most common in men 11th most common in women
4 Immunotherapy of urothelial cancers Exogenous Schistosomiasis Tobacco Phenacetin metabolites Cytostatics (Cyclophosphamides)? Sweeteners (Saccharin,cyclamate) Pelvic radiation Blackfoot disease (Taiwan) A. Fangchi (Chinese herb) Endogenous Chronic irritations (catheters) /Toxins Chronic inflammation Industrial Aniline dyes Benzene derivatives (aromatic amines) Paints, oils, gasoline Trytophan metabolites Nitrosamines
5 Immunotherapy of urothelial cancers
6 Immunotherapy of urothelial cancers Albert Calmette The Tuberculosis vaccine was invented in 1921 Attenuated form of the Mycobacterium bovis Produces local inflammatory reaction which will lead to stimulation of the T-cell function to destroy Superficial bladder cancer Cammile Guerin
7 Immunotherapy of urothelial cancers Bacillus Calmette Guerin (BCG) 1975 dekernion treated isolated melanoma in bladder with intravesical BCG 1976 Morales first successful use of intravesical BCG for superficial TCC Devised original protocol for induction 6 doses because Frappier strain packaged in 6 vials 120 mg/dose because tolerated by intradermal Weekly instillation because adverse effects <1 week 1978 Morales treated 10 patients and BCG reduced/eradicated tumor recurrences in7 2 randomized controlled trials SWOG (Lamm) and MSKCC conducted and confirmed reduced tumor recurrences compared to TURBT alone 1990 FDA approved intravesical BCG sources: HERR ET AL. J UROL2008: NCI presentation:agarwal
8 Immunotherapy of urothelial cancers Immune checkpoint Inhibitors: Introduction
9 Immunotherapy of urothelial cancers Immune checkpoint Inhibitors: Introduction APC, antigen presenting cell; MDSC, myeloid derived suppressor cell; M2, M2 macrophage; PD-L1, programmed cell death ligand 1; TCR, T cell receptor; TH1, T helper 1; TIL, tumourinfiltrating lymphocyte. Teng MWL et al. Cancer Res. 2015;75;
10 Immunotherapy of urothelial cancers: 2nd line Atezolizumab
11 Immunotherapy of urothelial cancers: 2nd line Atezolizumab
12 Immunotherapy of urothelial cancers: 2nd line Atezolizumab
13 Immunotherapy of urothelial cancers: 2nd line Atezolizumab
14 Immunotherapy of urothelial cancers: 2nd line Atezolizumab
15 Immunotherapy of urothelial cancers: 2nd line Atezolizumab
16 Immunotherapy of urothelial cancers: 2nd line pembrolizumab Module 5
17 Immunotherapy of urothelial cancers: 2nd line pembrolizumab Module 5 Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
18 Immunotherapy of urothelial cancers: 2nd line pembrolizumab Module 5 Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
19 Immunotherapy of urothelial cancers: 2nd line pembrolizumab Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
20 Immunotherapy of urothelial cancers: 2nd line pembrolizumab OS in all patients OS in patients with PD-L1 CPS 10% Adapted from: Fradet Y et al. ASCO Analysis cut-off date: 26 October a Based on Cox regression model with treatment as a covariate stratified by ECOG PS (0/1 vs 2), liver metastases (yes vs no), haemoglobin level (<10 vs 10 g/dl), and time from completion of chemotherapy (<3 vs 3 months). b One-sided P value based on stratified log-rank test. CI, confidence interval; CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PD-L1, programmed death ligand 1. Fradet Y et al. ASCO Chicago IL, June 1 5, Abstract 4521.
21 Immunotherapy of urothelial cancers pembrolizumab Presented By Joaquim Bellmunt at 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care
22 Immunotherapy of urothelial cancers pembrolizumab OS by best overall response (CR + PR) [n=87] Adapted from: Fradet Y et al. ASCO Analysis cut-off date: 26 October CI, confidence interval; CR, complete response; HR, hazard ratio; OS, overall survival; PR, partial response. Fradet Y et al. ASCO Chicago IL, June 1 5, Abstract 4521.
23 Immunotherapy of urothelial cancers first line chemotherapy (cisplatin ineligle patients) Maria de Santis et al, JCO 2012, 30,
24 Immunotherapy of urothelial cancers part 2 Module 3: first line chemotherapy (Response Rate) Best Overall Response Rate Gemcitabine/ Carboplatin Complete Response 3% Partial Response 38% Stable Disease 33% Progressieve Disease 15% Others 11% Maria de Santis et al, JCO 2012, 30,
25 Immunotherapy of urothelial cancers first line Pembrolizmab (cisplatin ineligible): Phase II Overall Survival Analysis cut-off date: 30 November OS, overall survival. 1. Vuky J et al. ASCO Chicago IL, June 1 5, Abstract 4524; 2. Balar AV et al. Lancet Oncol 2017;pii:S (17) Adapted from: Vuky J et al. ASCO 2018.
26 Immunotherapy of urothelial cancers first line Pembrolizmab (cisplatin ineligible): Phase II Response, n (%) 95% CI Objective response, n (%) 107 (29) Complete response 30 (8) Partial response 77 (21) Stable disease, n (%) 67 (18) Progressive disease, n (%) 156 (42) No assessment, n (%) 31 (8) Not evaluable, n (%) 9 (2) Adapted from: Vuky J et al. ASCO ORR was 24% in the total population in the primary analysis (analysis cut-off date: 1 September 2016) 2 Analysis cut-off date: 30 November Vuky J et al. ASCO Chicago IL, June 1 5, Abstract 4524; 2. Balar AV et al. Lancet Oncol 2017;pii:S (17) Adapted from: Vuky J et al. ASCO 2018.
27 Immunotherapy of urothelial cancers first line Pembrolizmab (cisplatin ineligible): Phase II PDL-1 CPS scoring and response rate EMA restricts use of anti-pd-1 drugs for bladder cancer Balar AV et al. Lancet oncology 2017:11; , updated Vuky J et al, ASCO 2018 Abstract 4524
28 Immunotherapy of urothelial cancers Immune checkpoint Inhibitors IgG antibodies and their Fc regions
29 Immunotherapy of urothelial cancers Module 3: Immune checkpoint Inhibitors Different IgG antibodies and different effects Anti-CTLA-4: in vivo based rationale Intra-tumoral Depletion of T-regs
30 Immunotherapy of urothelial cancers IgG1 wt Curetech Anti-PD-1 Merck/Pfizer Avelumab IgG4 hinge mutant BMS Anti-PD-1 Merck Anti-PD-1 ADCC intact Potential to deplete activated T cells and TILs and diminish activity Blocks PD-1/PD-L2 interaction in lungs Potential for autoimmune pneumonitis 40% reduced ADCC Potential to deplete activated T cells and TILs and diminish activity Blocks PD-1/PD-L2 interaction in lungs Potential for autoimmune pneumonitis at clinically relevant doses Courtesy of Dr. Herbst
31 Immunotherapy of urothelial cancers apd-1 apd-l1 NIVOLUMAB PEMBROLIZUMAB ATEZOLIZUMAB DURVALUMAB AVELUMAB IgG4 IgG4 Modified IgG1 Modified IgG1 IgG1 NO or modified ADCC / ADCP Infusion Related Reactions 3% ADCC / ADCP IRR 18%
32 TCGA, Nature, 2014 Immunotherapy of urothelial cancers part 2 Module 6: biomarkers for chemotherapy Urothelial Cancer is a molecularly heterogeneous disease
33 Immunotherapy of urothelial cancers Response on chemotherapy: ERCC2 mutations (Liu et al, Jama Oncol 2016) ATM, RB1, FANCC (DNA mismatched repair) (Plimack et al, Eur Urol 2015) Response on immunotherapy: PDL-1/PDL-2 expression Mutational load (Davarpanah et al, 2017) MDSC presence Curr Clin Opinion Tregs Response on Herceptin therapy: HER2/neu expression (Powles et al, JCO 2017) Response on mtor inhibitors: mutations in PI3K/AKT/mTOR pathway (Kortyglu et al, Clin Genit Cancer 2015) Response on FGFR3: FGFR3 mutation (Joerger et al, ESMO 2016) AR expression
34 Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer A. Gordon Robertson et al. Cell 2017
35 Immunotherapy of urothelial cancers Tom Powles, Kate Smith, Arnulf Stenzl, Jens Bedke European Urology
36 Anti-PD-1/ anti-pdl-1 nivolumab Immunotherapy of prostate cancer combination therapy combined with Vaccines (eg Prostvac) remarks nivolumab ipilimumab Neoantigen DNA vaccine, Prostvac, Biomarker driven, Immunogenic signature, enzalutamide pembrolizumab Olaparib, docetaxel, enzalutamide Phase III planned pembrolizumab DNA vaccines, Radium-223, ADX , CPI-444 atezolizumab Radium-223,Sipuleucel-T, Enzalutamide Phase III study enzalutamide avelumab Durvalumab Sipuleucel-T Tremulimumab Regn2810 Ipilimumab (intraprostatic) + stereotactic RT
37 Prostate cancer immunogenic subtypes identified by WGS 15-25% of patients have an immunogenic molecular signature 7.7% have htmb (>10 mut/mb) 6.7% of patients have a htmb /MSI signature 1% of patients have BRCA inactivation 6.7% of patients have CDK12 biallelic inactivation and tandem duplication signature 1 12% have BRCAness Enrichment of aberrations in htmb tumours MMR genes (MSH6, MSH2, MLH1) Non-synonymous variants in POLE Recurrent frameshift mutations 2 in relevant genes including ACVR2A, JAK1 and TGFBR2 Aberrations in known prostate cancer drivers ZFHX3, PALB2 Novel potential (immuno)suppressive genes TTK, CIC, ZFP36L2, EPA1, KMT2C, SETD1B, ZMYM3 and others 1. Wu YM et al. Cell 2018; 173(7): /11/ Kim T-M et al. Cell 2013;155(4):
38 Immunotherapy of prostate cancer selection of patients MICROSATELLITE INSTABILITY IN PROSTATE CANCER AND RESPONSE TO IMMUNE CHECKPOINT BLOCKADE WASSIM ABIDA ET AL. ASCO 2018 ABSTRACT 5020
39 Immunotherapy of prostate cancer selection of patients
40 Immunotherapy of prostate cancer selection of patients Radboudumc experience: Nivolumab in MSI high & sanctuary sites PSMA - PET scan
41 Conclusions Urothelial cancers: First and second line: immune checkpoint inhibitors First line (platinum ineligible): restricted use based on PDL-1 expression Different mode of action NGS data become more important Prostate cancer: New immunotherapy trials 20-25% eligible for immunotherapy, especially MSI high Be aware of sanctuary sites
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationNuove opzioni terapeutiche nel Carcinoma della Prostata: IMMUNOTERAPIA. Andrea Sbrana U.O. Oncologia Medica 2 Universitaria AOU Pisana
Nuove opzioni terapeutiche nel Carcinoma della Prostata: IMMUNOTERAPIA Andrea Sbrana U.O. Oncologia Medica 2 Universitaria AOU Pisana Until now: Some success Kantoff et al, N Engl J Med 2010 Kantoff et
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationDaniel Lieber, Ph.D. Senior Scientist, Computational Biology Foundation Medicine, Cambridge, MA. AACR 2017: Clinical Biomarkers April 3, 2017
Validation & clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Daniel Lieber, Ph.D. Senior Scientist, Computational
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationIs Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015
Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 J. J. Mulé Associate Center Director, Translational Research U.S. Senator Connie Mack & Family
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy for Genitourinary Cancers. Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI
Immunotherapy for Genitourinary Cancers Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI Disclosures Madison Vaccines Inc co-founder, IP, consultant
More informationIs Immune Therapy for Prostate Cancer a Riddle Wrapped Up in an Enigma?
Is Immune Therapy for Prostate Cancer a Riddle Wrapped Up in an Enigma? Susan F. Slovin, MD, PhD Attending Physician, Member Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationUrothelial Carcinoma Highlights
Urothelial Carcinoma Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano European Association of Urology Research Foundation Disclosures Consulting or Advisory Role: Company:
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationImmunotherapy and new agents in CRPC. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Immunotherapy and new agents in CRPC Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas, Astrazeneca, Bayer, Clovis,
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationAdvanced Bladder Cancer: Check Mate or Check Point Inhibitors
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors Daniel P Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationTumori Genito-Urinari. Fabio Calabrò Oncologia Medica Azienda Ospedaliera San Camillo Forlanini
Tumori Genito-Urinari Fabio Calabrò Oncologia Medica Azienda Ospedaliera San Camillo Forlanini Prostate cancer treatment paradigm is evolving PROSTATE CANCER TREATMENT PARADIGMIS EVOLVING Non metatasticcrpc
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationIntegrating Immunotherapy into Urologic Oncology: The New Urothelial Cancer Paradigm
Immunotherapy in Urothelial Cancer: Where are We Now & Where are We Going? Arjun Balar, MD Director of Genitourinary Medical Oncology Program NYU Langone Medical Center New York, NY Bladder Cancer Therapeutic
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationOptimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL
Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma Moran Gadot M.D SHEBA Medical Center ISRAEL Disclosures none All (eligible) patients should get chemotherapy
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationCarla van Herpen Medical Oncologist Immunotherapyin Head & NeckCancer
Carla van Herpen Medical Oncologist 01-10-2016 Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial,
More informationSpecial Situation: Brain metastases
ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationCombination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy
Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures
More informationAVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationThe Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationNovel therapeutic strategies for NMIBC. Peter Black Vancouver Prostate Centre University of British Columbia
Novel therapeutic strategies for NMIBC Peter Black Vancouver Prostate Centre University of British Columbia Financial and Other Disclosures I have the following financial interests or relationships to
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationHistorical overview of immunotherapy
Historical overview of immunotherapy Before introduction of immune checkpoint inhibitors John B.A.G. Haanen, MD PhD My Disclosures I have provided consultation, attended advisory boards, and/or provided
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationChallenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University OS PCG 15.8 vs GC 12.7 NS Cisplatin ineligible Second-line chemotherapy
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Royal Marsden Hospital ESMO Colorectal Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role Servier, Celgene, BMS, Five
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationDisclosure. Astellas. Research funding. Advisory board (to institute) Roche/Genentech Astra Zeneca/Medimmune Astellas
Disclosure Activity Company Research funding Advisory board (to institute) Astellas Roche/Genentech Astra Zeneca/Medimmune Astellas Immunotherapy for urothelial cell carcinoma A NEW HOPE Michiel van der
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
More informationChallenging Genitourinary Tumors: What s New in 2017
Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More information